Pro members get actionable news alerts up to 30 minutes before other traders — Get our lowest prices
Pro members get actionable news alerts up to 30 minutes before other traders — Get our lowest prices
Immunic Inc has a consensus price target of $17.75 based on the ratings of 8 analysts. The high is $35 issued by Aegis Capital on August 8, 2022. The low is $5 issued by SVB Leerink on October 21, 2022. The 3 most-recent analyst ratings were released by B. Riley Securities, Piper Sandler, and Brookline Capital on August 27, 2024, July 16, 2024, and April 5, 2024, respectively. With an average price target of $14.67 between B. Riley Securities, Piper Sandler, and Brookline Capital, there's an implied 970.56% upside for Immunic Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Immunic (NASDAQ:IMUX) was reported by B. Riley Securities on August 27, 2024. The analyst firm set a price target for $6.00 expecting IMUX to rise to within 12 months (a possible 337.96% upside). 4 analyst firms have reported ratings in the last year.
The latest analyst rating for Immunic (NASDAQ:IMUX) was provided by B. Riley Securities, and Immunic initiated their buy rating.
There is no last upgrade for Immunic
The last downgrade for Immunic Inc happened on October 21, 2022 when SVB Leerink changed their price target from $9 to $5 for Immunic Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immunic, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immunic was filed on August 27, 2024 so you should expect the next rating to be made available sometime around August 27, 2025.
While ratings are subjective and will change, the latest Immunic (IMUX) rating was a initiated with a price target of $0.00 to $6.00. The current price Immunic (IMUX) is trading at is $1.37, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.